Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 25Lymphoma, Large B-Cell, Diffuse 23Burkitt Lymphoma 16Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Non-Hodgkin 9Lymphoma, Follicular 9Neoplasm Metastasis 7Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 6Lymphoma, B-Cell 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 5Lymphoma, T-Cell, Peripheral 5Leukemia 5Recurrence 4Neoplasms 4Lymphoma, T-Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Carcinoma, Non-Small-Cell Lung 3Thrombocythemia, Essential 2Primary Myelofibrosis 2

Interventions

cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Hormone Refractory Prostate Cancer × Prednisone × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡